Literature DB >> 7601951

Endoscopic transthoracic sympathectomy: an efficient and safe method for the treatment of hyperhidrosis.

C Drott1, G Göthberg, G Claes.   

Abstract

BACKGROUND: Hyperhidrosis of the palms, axillae, and face has a strong negative impact on the quality of life for many persons. Existing nonsurgical therapeutic options are far from ideal. Definitive cure can be obtained by upper thoracic sympathectomy. The traditional open surgical technique is a major procedure; few patients and doctors have found that risk-benefit considerations favor surgery. Endoscopic minimal invasive surgical techniques are now available.
OBJECTIVE: We investigated whether endoscopic ablation of the upper thoracic sympathetic chain is efficient and safe in the treatment of hyperhidrosis.
METHODS: We treated 850 patients with bilateral endoscopic transthoracic sympathectomy.
RESULTS: There was no mortality or life-threatening complication. Nine patients (1%) required intercostal drainage because of hemothorax or pneumothorax. Treatment failure occurred in 18 cases (2%) and symptoms recurred in 17 patients (2%). At the end of follow-up (median, 31 months) 98% of the patients reported satisfactory results.
CONCLUSION: Endoscopic transthoracic sympathectomy is an efficient, safe, and minimally invasive surgical method for the treatment of palmar, axillary, and facial hyperhidrosis.

Entities:  

Mesh:

Year:  1995        PMID: 7601951     DOI: 10.1016/0190-9622(95)90015-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  23 in total

Review 1.  Thoracoscopic sympathectomy for palmar hyperhidrosis. Ablate or resect?

Authors:  M Hashmonai; A Assalia; D Kopelman
Journal:  Surg Endosc       Date:  2001-04-03       Impact factor: 4.584

2.  Thoracic sympathicolysis for primary hyperhidrosis: a review of 918 procedures.

Authors:  J Moya; R Ramos; R Morera; R Villalonga; V Perna; I Macia; G Ferrer
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

3.  [Treatment of palmar and axillary hyperhidrosis: thoracoscopic resection of the sympathetic chain].

Authors:  R Rieger; S Pedevilla; S Pöchlauer
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

4.  A novel online method to monitor autonomic nervous activity based on arterial wall impedance and heart rate variability.

Authors:  Abdugheni Kutluk; Toshio Tsuji; Teiji Ukawa; Ryuji Nakamura; Noboru Saeki; Masao Yoshizumi; Masashi Kawamoto
Journal:  Med Biol Eng Comput       Date:  2010-02-02       Impact factor: 2.602

5.  Chylothorax after endoscopic thoracic sympathectomy.

Authors:  D Gossot
Journal:  Surg Endosc       Date:  1996-09       Impact factor: 4.584

6.  Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.

Authors:  M Naumann; N J Lowe
Journal:  BMJ       Date:  2001-09-15

7.  The body mass index and level of resection: predictive factors for compensatory sweating after sympathectomy.

Authors:  José Ribas Milanez de Campos; Nelson Wolosker; Flavio Roberto Takeda; Paulo Kauffman; Sergio Kuzniec; Fábio Biscegli Jatene; Sérgio Almeida de Oliveira
Journal:  Clin Auton Res       Date:  2005-04       Impact factor: 4.435

8.  Long-term results of a randomized controlled trial of T2 versus T2-T3 ablation in endoscopic thoracic sympathectomy for palmar hyperhidrosis.

Authors:  Wilson Ong; Alvin Lee; Wee Boon Tan; Davide Lomanto
Journal:  Surg Endosc       Date:  2015-07-07       Impact factor: 4.584

9.  Sympathetic nerve reconstruction for compensatory hyperhidrosis after sympathetic surgery for primary hyperhidrosis.

Authors:  Seok Jin Haam; Seung Yong Park; Hyo Chae Paik; Doo Yun Lee
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

10.  Twenty months of evolution following sympathectomy on patients with palmar hyperhidrosis: sympathectomy at the T3 level is better than at the T2 level.

Authors:  Guilherme Yazbek; Nelson Wolosker; Paulo Kauffman; José Ribas Milanez de Campos; Pedro Puech-Leão; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.